NanoLogix Bacteria Detection Plates Break Longevity Records Using Anthrax as Reference Bacteria

HUBBARD, Ohio --(Business Wire)--

NanoLogix Inc. (OTC: NNLX), the biotechnology company focused primarily on rapid diagnostics, is pleased to announce independent tests show extraordinary success in testing of a revolutionary new packaging technology for the long-term, room-temperature storage of Petri plates used for bacteria detection. Tested with Anthrax as reference bacteria, and designed for use in detection of a multitude of bacteria, this achievement may be the biggest single improvement to century-old Petri-dish-based technology in decades.

NanoLogix nitrogen-charged FlatPack Petri plates stored at room temperature for six months provided growth and detection of Anthrax equivalent to competitor's new Petri plates, according to results of third-party testing conducted by a large independent laboratory. The nationally known competitor's product delivered degraded results after just two months, the lab said, citing results after testing had reached a six-month comparison point. All tests were conducted using Tryptic Soy Agar (TSA), a world standard nutrient agar for bacterial detection. The tests also demonstrated an astonishingly reduced time to results of 14 hours for detection of Anthrax with NanoLogix FlatPack TSA, compared to historic norms of 24 hours using the competitor TSA.

FlatPack room-temperature preservation technology leapfrogs current standards, under which TSA petri plates remain usable for only three months in cold storage - that is, 2 to 8 degrees Centigrade, or 36 to 46 degrees Fahrenheit, according to NanoLogix. FlatPack technology eliminates the need for refrigeration of TSA and extends the usable life of the TSA agar by multiples of what is available from competitors. In addition, FlatPack technology provides for easy visibility of all ten plates per pack for quality inspection, and reduces or eliminates breakage during shipping and storage. After shiping tens of thousands of plates, NanoLogix has been told by customers that not a single plate has broken.

The testing showed reduced results for the competitor's Petri plates after the first two months of testing at room temperatures. At that point, NanoLogix Petri plates provided results essentially identical to new plates. After four months at room temperature, the nutrient agar in the competitor's Petri plates had completely dried out and was unusable for detection, while NanoLogix's Petri plates again provided identical results to new plates, the third-party lab said.

After five and six months at room temperature, due to the desiccated nature of the agar in the competitor's Petri plates, the lab changed comparison for control purposes to compare NanoLogix's Petri plates to the competitor's fresh, just-delivered nutrient plates. At both data points, NanoLogix's Flatpack-preserved Petri plates provided the equivalent in detection results to fresh Petri plates.

The current testing process, a follow-up to the successful one-year cold storage tests for NanoLogix TSA that were completed in 2012, will continue for an additional six months.

NanoLogix to Exhibit at the American Society for Microbiology (ASM (News - Alert)) BioDefense and Emerging
Diseases Research Meeting in Washington DC, 25-27 February 2013.

The Company will exhibit its technology at booth 38 in the MARRIOTT WARDMAN PARK - HALLS B SOUTH & C, 2660 Woodley Rd. NW, Washington, DC 20008

Additional information regarding the meeting can be found at the following link:

http://www.asmbiodefense.org/

About NanoLogix, Inc.

NanoLogix is a biotechnology company focused primarily on rapid diagnostics. Its products offer accelerated detection and identification of microorganisms. In addition to medical and homeland security applications, NanoLogix technology is applicable in pharmaceutical, industrial, veterinary and environmental testing.

Patents granted to NanoLogix can be used in the areas of applied microbiology, soil microbiology and bioremediation, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, and antibiotic sensitivity

For more information visit www.nanologix.com.

This press release contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.